We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Moderna (MRNA) Stock Moves -0.35%: What You Should Know
Read MoreHide Full Article
Moderna (MRNA - Free Report) closed at $47.88 in the latest trading session, marking a -0.35% move from the prior day. This change was narrower than the S&P 500's daily loss of 0.52%. Meanwhile, the Dow lost 0.13%, and the Nasdaq, a tech-heavy index, lost 1.4%.
Heading into today, shares of the biotechnology company had gained 57.64% over the past month, outpacing the Medical sector's gain of 17.7% and the S&P 500's gain of 13.35% in that time.
MRNA will be looking to display strength as it nears its next earnings release, which is expected to be May 7, 2020. The company is expected to report EPS of -$0.37, up 7.5% from the prior-year quarter. Our most recent consensus estimate is calling for quarterly revenue of $18.17 million, up 13.33% from the year-ago period.
MRNA's full-year Zacks Consensus Estimates are calling for earnings of -$1.51 per share and revenue of $77.64 million. These results would represent year-over-year changes of +2.58% and +28.95%, respectively.
It is also important to note the recent changes to analyst estimates for MRNA. These revisions typically reflect the latest short-term business trends, which can change frequently. As a result, we can interpret positive estimate revisions as a good sign for the company's business outlook.
Research indicates that these estimate revisions are directly correlated with near-term share price momentum. To benefit from this, we have developed the Zacks Rank, a proprietary model which takes these estimate changes into account and provides an actionable rating system.
The Zacks Rank system ranges from #1 (Strong Buy) to #5 (Strong Sell). It has a remarkable, outside-audited track record of success, with #1 stocks delivering an average annual return of +25% since 1988. Within the past 30 days, our consensus EPS projection remained stagnant. MRNA is currently sporting a Zacks Rank of #1 (Strong Buy).
The Medical - Biomedical and Genetics industry is part of the Medical sector. This group has a Zacks Industry Rank of 13, putting it in the top 6% of all 250+ industries.
The Zacks Industry Rank includes is listed in order from best to worst in terms of the average Zacks Rank of the individual companies within each of these sectors. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
To follow MRNA in the coming trading sessions, be sure to utilize Zacks.com.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Moderna (MRNA) Stock Moves -0.35%: What You Should Know
Moderna (MRNA - Free Report) closed at $47.88 in the latest trading session, marking a -0.35% move from the prior day. This change was narrower than the S&P 500's daily loss of 0.52%. Meanwhile, the Dow lost 0.13%, and the Nasdaq, a tech-heavy index, lost 1.4%.
Heading into today, shares of the biotechnology company had gained 57.64% over the past month, outpacing the Medical sector's gain of 17.7% and the S&P 500's gain of 13.35% in that time.
MRNA will be looking to display strength as it nears its next earnings release, which is expected to be May 7, 2020. The company is expected to report EPS of -$0.37, up 7.5% from the prior-year quarter. Our most recent consensus estimate is calling for quarterly revenue of $18.17 million, up 13.33% from the year-ago period.
MRNA's full-year Zacks Consensus Estimates are calling for earnings of -$1.51 per share and revenue of $77.64 million. These results would represent year-over-year changes of +2.58% and +28.95%, respectively.
It is also important to note the recent changes to analyst estimates for MRNA. These revisions typically reflect the latest short-term business trends, which can change frequently. As a result, we can interpret positive estimate revisions as a good sign for the company's business outlook.
Research indicates that these estimate revisions are directly correlated with near-term share price momentum. To benefit from this, we have developed the Zacks Rank, a proprietary model which takes these estimate changes into account and provides an actionable rating system.
The Zacks Rank system ranges from #1 (Strong Buy) to #5 (Strong Sell). It has a remarkable, outside-audited track record of success, with #1 stocks delivering an average annual return of +25% since 1988. Within the past 30 days, our consensus EPS projection remained stagnant. MRNA is currently sporting a Zacks Rank of #1 (Strong Buy).
The Medical - Biomedical and Genetics industry is part of the Medical sector. This group has a Zacks Industry Rank of 13, putting it in the top 6% of all 250+ industries.
The Zacks Industry Rank includes is listed in order from best to worst in terms of the average Zacks Rank of the individual companies within each of these sectors. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
To follow MRNA in the coming trading sessions, be sure to utilize Zacks.com.